Haemonetics Corporation (HAE)
Profitability ratios
Return on sales
| Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | |
|---|---|---|---|---|---|
| Gross profit margin | 55.04% | 52.83% | 52.63% | 50.90% | 45.70% |
| Operating profit margin | 16.30% | 12.60% | 13.35% | 8.13% | 6.66% |
| Pretax margin | 15.58% | 11.60% | 12.10% | 6.41% | 8.38% |
| Net profit margin | 12.32% | 8.98% | 9.87% | 4.37% | 9.13% |
Haemonetics Corporation has shown a consistent improvement in its profitability ratios over the past five years. The Gross Profit Margin has increased steadily from 45.70% in March 31, 2021 to 55.04% in March 31, 2025, indicating the company's ability to effectively control its production costs and generate higher margins on its products.
The Operating Profit Margin has also exhibited a positive trend, rising from 6.66% in March 31, 2021 to 16.30% in March 31, 2025. This indicates that the company has efficiently managed its operating expenses and has been able to increase profitability from its core business operations.
The Pretax Margin has shown significant improvement as well, climbing from 8.38% in March 31, 2021 to 15.58% in March 31, 2025. This suggests that Haemonetics has been successful in enhancing its overall operational efficiency and effectiveness in generating pre-tax profits.
Finally, the Net Profit Margin has experienced growth from 9.13% in March 31, 2021 to 12.32% in March 31, 2025. This indicates that the company has been able to effectively manage its costs, taxes, and interest expenses to generate a higher percentage of net income compared to its total revenue.
Overall, Haemonetics Corporation's profitability ratios demonstrate a positive trend, reflecting the company's ability to enhance profitability and efficiency in its operations over the analyzed period.
Return on investment
| Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 9.05% | 7.51% | 8.06% | 4.34% | 3.18% |
| Return on assets (ROA) | 6.84% | 5.35% | 5.96% | 2.33% | 4.37% |
| Return on total capital | 0.00% | 17.54% | 19.08% | 10.77% | 7.92% |
| Return on equity (ROE) | 20.43% | 12.25% | 14.11% | 5.79% | 10.86% |
Haemonetics Corporation's profitability ratios show varying performance over the years.
- Operating return on assets (Operating ROA) has been on an upward trend, increasing from 3.18% in March 2021 to 8.06% in March 2023, before slightly decreasing to 7.51% in March 2024. This indicates that the company is generating more operating income per dollar of assets employed, showcasing improving operational efficiency.
- Return on assets (ROA) experienced fluctuations, dropping from 4.37% in March 2021 to 2.33% in March 2022, before rebounding to 5.96% in March 2023 and then stabilizing at 5.35% in March 2024. ROA reflects the overall profitability of the company's assets, and the fluctuations suggest mixed results in utilizing assets to generate earnings.
- Return on total capital demonstrates a positive trend, rising from 7.92% in March 2021 to 19.08% in March 2023, demonstrating the company's ability to generate returns on the total capital invested. This ratio indicates the efficiency of using all sources of capital to generate profits.
- Return on equity (ROE) experienced a decline in March 2022 but recovered in subsequent years, reaching 14.11% in March 2023 before slightly decreasing to 12.25% in March 2024. ROE measures the return generated on shareholders' equity, and the fluctuations suggest varying profitability levels related to the equity investment.
Overall, the company's profitability ratios depict a mixed performance, with improvements in certain areas such as Operating ROA and Return on total capital, while showing fluctuations in ROA and ROE. Continuous monitoring and analysis of these ratios can provide insights into Haemonetics Corporation's financial efficiency and performance over time.